

Company Overview

Pressure BioSciences, Inc. develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.

To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

Richard T. Schumacher, CEO of Pressure BioSciences, Inc., Discusses Strong Finish to 2017 and Operational Developments for 2018 on Uptick Newswire's "Stock Day" Podcast with Everett Jolly

Apr 10 2018, 11:38 AM EDT

Pressure BioSciences, Inc. Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Provides Business Update

Apr 3 2018, 4:30 PM EDT

Stock Overview

Symbol	PBIO
Exchange	OTCQB
Shares OS	1,367,852
Market Cap	\$4.79M
Last Price	\$3.50
52-Week	\$0.70 - \$9.897

04/20/2018 03:10 PM EDT

Investor Relations

Pressure BioSciences, Inc.
Richard T. Schumacher
CEO & Founder
14 Norfolk Avenue
South Easton, MA 02375
T: (508) 230-1828
F: (508) 230-1829
ir@pressurebiosciences.com

Management Team

Richard T. Schumacher

President, Chief Executive Officer and Director

Edmund Ting, Ph.D.

Senior Vice President of Engineering

Nathan P. Lawrence, Ph.D.

Vice President of Marketing and Sales

Alexander Lazarev, Ph.D.

Vice President of Research and Development

Joseph L. Damasio Jr.

Vice President of Finance and Chief Financial Officer

Pressure BioSciences, Inc.

14 Norfolk Avenue
South Easton, MA 02375

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.